EpiCept Corporation to Present at the New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference


TARRYTOWN, N.Y., Dec. 5 / -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley, President and CEO, will present a company overview at the New York Society of Security Analysts ("NYSSA") 11th Annual Biotech & Specialty Pharma Conference on December 12, 2007 at 4:05 p.m. Eastern Time. The conference will be held at the NYSSA's headquarters at 1177 Avenue of the Americas in New York City.

The presentation will be available live via webcast on December 12, 2007. The webcast can be accessed by visiting www.epicept.com. A replay of the presentation will be available for 90 days following the event.

About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high- throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Source: EpiCept Corporation

CONTACT: Robert W. Cook of EpiCept Corporation, +1-914-606-3500, rcook@epicept.com; or Media, Greg Kelley of Feinstein Kean Healthcare,
+1-617-577-8110, gregory.kelley@fkhealth.com; or Investors, Kim Sutton
Golodetz, +1-212-838-3777, kgolodetz@lhai.com, or Bruce Voss, +1-310-691-7100, bvoss@lhai.com, both of Lippert/Heilshorn & Associates; all for EpiCept Corporation

Web site: www.epicept.com/

All Topics